Every 424B that Rocket Lab Usa Inc (RKLB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RKLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RKLB filings page.
Rocket Lab Corp (RKLB) has filed a merger proxy/prospectus covering its agreed acquisition of Iridium Communications Inc. Iridium will become an indirect, wholly owned subsidiary of Rocket Lab and its stock will be delisted from Nasdaq after closing.
Each Iridium share will be converted into the right to receive $27.00 in cash plus Rocket Lab common stock based on an exchange ratio capped by a collar: 0.4000 shares if the Rocket Lab stock price is ≤ $67.50, 0.2400 shares if ≥ $112.50, and otherwise $27.00 divided by the Rocket Lab stock price. No fractional Rocket Lab shares will be issued; cash will be paid in lieu of fractions.
The merger requires approval by a majority of Iridium shares outstanding at a virtual special meeting on September 24, 2026, with a record date of August 21, 2026, and is subject to regulatory clearances and other customary conditions. Rocket Lab plans to fund the cash consideration using balance sheet cash and external financing, including commitments for a $3.6 billion senior secured bridge facility. If certain termination scenarios occur, Iridium must pay Rocket Lab a $223.6 million termination fee.
Rocket Lab Corporation established a new at-the-market equity program allowing sales of up to $1,944,369,826 of common stock, replacing capacity remaining under a prior $3.0 billion equity distribution agreement. Deutsche Bank Securities and Wells Fargo Securities act as sales agents and as intermediaries for complex forward and collared forward sale structures.
The company may sell shares directly or via forward purchasers that borrow and sell stock, with Rocket Lab receiving cash later upon physical or certain cash settlements. Proceeds are intended primarily to fund the cash portion of the proposed Iridium Communications acquisition, related fees, potential repayment of Iridium debt, and to reduce a $3,600.0 million bridge loan commitment; excess funds may support other growth and general corporate purposes.
The offering is not conditioned on closing the Iridium transaction, can be executed over time at prevailing Nasdaq prices, and may dilute earnings per share when shares are issued or upon settlement of forward transactions. Commissions to agents and forward sellers may be up to 2.0% of sale prices.
Rocket Lab Corporation registered an at-the-market equity program to offer up to $3,000,000,000 of common stock under a prospectus supplement dated May 20, 2026. The company may sell shares through appointed sales agents or enter into forward and collared forward transactions with specified financial counterparties.
The supplement states Rocket Lab will not initially receive proceeds from sales of borrowed hedging shares, expects to receive cash upon physical settlement or certain prepayments, and may use net proceeds to fund growth, potential acquisitions and general corporate purposes. The offering is subject to FINRA Rule 5121 conflict-of-interest procedures.
Rocket Lab Corporation filed a prospectus supplement registering 2,277,002 shares of its common stock for resale by selling stockholders. These shares were issued on April 14, 2026 as partial consideration for the acquisition of Mynaric AG. The company will not receive any proceeds from sales of the registered shares; proceeds will go to the selling stockholders. Shares outstanding were 578,750,990 as of April 30, 2026. The prospectus supplement states the shares may be sold on Nasdaq, in OTC trades, privately negotiated transactions or other permitted methods under the Plan of Distribution.
Rocket Lab Corporation is registering and may sell up to $1,000,000,000 of its common stock via an "at-the-market" equity distribution agreement with multiple sales agents and related forward sale structures.
The prospectus supplement terminates a prior $750,000,000 sales agreement and permits sales through sales agents acting as agents or principals, as well as forward transactions ("initially priced" and "collared" forwards) with specified forward purchasers. Proceeds from initially priced and collared forward transactions are expected to be received on physical settlement or certain prepayment dates; cash or net-share settlement is possible and may result in payments by Rocket Lab or issuance of shares. Commissions to sales agents and forward sellers may be up to 2.0%. The company’s common stock trades on Nasdaq under the symbol RKLB; last reported sale price was $71.31 per share on March 16, 2026.